NEW YORK, NY - October 14, 2025 - B2i Digital announced that eXoZymes Inc. (EXOZ) has been named a Featured Company, aiming to spotlight the company's cell-free, AI-guided enzyme platform. eXoZymes develops exozymes—advanced enzymes enhanced through AI and bioengineering—that operate in bioreactors without living cells, transforming biomass into natural products, medicines, chemicals, and biofuels. This approach targets the scale-up bottleneck seen in first-generation synthetic biology, offering a lower-impact alternative to petrochemical processes, natural extraction, and synthetic biology.
David Shapiro, CEO of B2i Digital, stated, “We look forward to introducing eXoZymes to our sophisticated investor community. With its cell-free enzyme technology that targets the scale-up bottleneck seen in first-generation synthetic biology, the company offers a timely story for investors focused on sustainable industrial biotechnology. The platform aims to replace selected petrochemical processes with lower-impact biosolutions.”
Michael Heltzen, CEO of eXoZymes, commented, “As we're leading the 4th industrial revolution at the intersection of biology and technology, our partnership with B2i Digital will assist our efforts to communicate our cell-free biomanufacturing and the commercial potential of our exozymes platform to the investment community. We believe that the next generation of biomanufacturing is cell-free and as we advance partnerships, this collaboration will enhance our visibility among investors who understand the value of our scalable enzyme-based approach as an alternative to petrochemical processes, natural extraction, and synthetic biology.”
The partnership underscores eXoZymes' strategy to initially target low volume, high value natural products—like NCT—with potential pharmaceutical applications. By freeing enzyme-driven reactions from cellular constraints, eXoZymes provides a commercially viable path to scalable and sustainable production of small molecules at industrial scale. The company's exozymes are designed to thrive in bioreactors, enabling partners to design and run enzyme pathways for target chemicals.
B2i Digital, which partners with leading investor conferences and capital markets advisors, will feature eXoZymes through its Featured Company program, delivering boardroom-caliber investor engagement. The firm's proprietary network of over 1.4 million market participants will help eXoZymes gain visibility among investors focused on sustainable industrial biotechnology.
For more information about eXoZymes, visit exozymes.com. To learn more about B2i Digital, visit b2idigital.com.
